Tandem Diabetes Care announced that its t:slim X2 insulin pump with Control-IQ+ technology now integrates with Abbott's FreeStyle Libre 3 Plus continuous glucose monitor across five European countries. The company's annual revenue exceeds $1,027.535 million, yet its share price has fallen 28.49% year to date to $15.41. A popular investor narrative on Simply Wall St sets a fair value of $29.20 per share, suggesting the stock is 47.2% undervalued based on long-term earnings potential. Broader pharmacy channel expansion is expected to lower out-of-pocket costs and increase pump adoption, supporting future revenue growth and margin expansion. However, the outlook also carries execution and competitive risks, including rising pump competition and flat renewal expectations.
Tandem Diabetes Care IncTandem's t:slim X2 pump now integrates with Abbott's CGM in five European countries, expanding product capability.
Abbott LaboratoriesAbbott's FreeStyle Libre 3 Plus is integrated with Tandem's pump, potentially boosting sensor demand.